Xenotransplantation: Risks, Clinical Potential, and Future Prospects

The reemergence of xenotransplantation as a therapeutic option for the hundreds of thousands of people dying each year of heart, kidney, lung, and liver failure has raised ethical, social, and scientific questions. End-stage organ failure is one of the most important public health problems facing Americans today. Heart failure, for example, kills four times as many people as does HIV infection and three times as many people as does breast cancer; it is a disease with an increasing incidence, and the cost of taking care of affected patients is 8 to 35 billion dollars each year. The single most effective therapy for it is transplantation. Preventive therapies have had little impact on diseases due to end-stage organ failure and are unlikely to have an impact at least in the next decade. In the meantime, demand for organs, which far outstrips the supply, continues to grow. It has been estimated that approximately 45,000 Americans under age 65 could benefit each year from heart transplantation, yet only 2,000 human hearts are available annually. Patients are more likely to die waiting for a human donor heart than in the first 2 years after transplantation.

Although clearly an experimental procedure, xenotransplantation between closely related species, such as baboons and humans, offers an alternative to allotransplantation as a source of human organ replacement. Alternatives to allograft donors, such as baboon or pig xenografts, require serious investigation if clinical transplantation is ever to meet the current demand and continue the explosive growth pattern it has established over the past quarter century.

Biologic cardiac replacement poses the immunologic problems of rejection and infection associated with transplantation. Increasing clinical experience worldwide has shown that rejection and infection can be managed successfully in most patients who receive human cardiac allografts. Further, the introduction of cyclosporine as the primary immunosuppressive agent for cardiac transplant recipients has resulted in excellent survival rates (85% 1-year survival at most centers) and has decreased illness associated with infection and rejection. Although considerable advances have been made in the field of cardiac xenotransplantation since its first clinical application by Hardy in 1964 (1), it remains uncertain whether xenotransplantation as destination therapy can be successfully applied to humans. However, heart, kidney, and liver xenografts have been able to support human life for an extended period. It is this fact that investigators wish to exploit in clinical bridging studies. By providing temporary heart, kidney, or liver support as a bridge-to-transplantation, these biological devices may allow patients to recover end-organ function and await allograft transplantation in a more stable clinical state, thus improving their chances of survival. Bridging strategies cannot alleviate the human organ donor shortage. However, if one views bridging strategies as a first feasibility test, then cross-species transplantation does offer the possibility of eventual long-term organ replacement. Success in this more ambitious goal would help alleviate the human organ donor shortage.

Nonhuman primate organ donors have been favored by those wishing to minimize the genetic disparity between donors and human recipients. Chimpanzees, although most compatible with standard selection criteria (e.g., compatibility of size and blood types), are unavailable as an acceptable source of clinical xenotransplantation. Another choice is the baboon, which is not endangered, has an anatomy and physiology similar to those of humans, and grows to a weight of approximately 70 pounds. Baboon size would limit the clinical application of xenotransplantation with baboon organs to pediatric patients and small adults. Small body size, the infrequency of blood group O (universal donor) animals, and the limited number of colony-bred animals are distinct disadvantages to the baboon as a donor.

Extended graft survival is possible, but ABO blood group compatibility is mandatory before xenotransplantation (2). The distribution of ABO blood groups found in baboons indicates that approximately one third are group A, one-third group B, and one-third group AB. Universal donor group O, however, is exceedingly rare. In Americans of Western European descent, the relative frequency of blood types is approximately 45% group A, 8% group B, 4% group AB, and 43% group O (2).

Although available in large numbers, wild baboons are not suitable from an infectious disease perspective. Most experts have suggested that colony-bred animals represent a more suitable donor pool. However, these animals number only in the hundreds and are, therefore, only likely to
partially meet the epidemiologic demands of the pediatric population with end-stage organ failure.

Xenotransplantation between baboons and humans raises the issue of xenozoonoses (3,4). The organisms of greatest concern are the herpesviruses and retroviruses, which can be screened for and eliminated from the donor pool. Others include Toxoplasma gondii, Mycobacterium tuberculosis, and encephalomyocarditis virus. Less likely to be found in animals raised in captivity in the United States are the filoviruses (Marburg and Ebola), monkeypox, and Simian hemorrhagic fever virus. Organisms that are unlikely to be transmitted with an organ transplant (but should be screened for) include lymphocytic choriomeningitis virus, gastrointestinal parasites, and GI bacterial pathogens.

The risk for xenozoonoses is likely to be restricted to the xenogeneic tissue recipient. Nevertheless, one must consider and anticipate the potential for xenozoonotic transmission through the human population, constituting a public health concern. The risk for recognized zoonotic pathogens can be reduced, if not eliminated, by controlling the donor animal vendor source and the individual donor animal by employing described screening tests and strict sterile procedures during organ harvesting and donor autopsy for tissue and blood. The risk for unrecognized pathogens is present but ill defined.

Surveillance for the transmission of known or unknown pathogens among health care workers must be conducted by monitoring for unexpected or unexplained adverse health events. It is difficult to monitor for the unknown; therefore, surveillance should include notifying the principal investigator's office of any unexplained illness in exposed health care workers, as well as telephone interviews of these personnel every 6 months by the principal investigator's office.

Concurrent with scientific advances in xenotransplantation have been the necessary ethical debates concerning the appropriateness of this endeavor (5). Disputes regarding animal experimentation notwithstanding, the ethical issues raised by many of these debates are strikingly similar to those put forth 25 years ago in reference to the (then new) field of human heart transplantation. Indeed, the timeless nature of these queries itself attests to their essence, for such ethical concerns are appropriate in the appraisal of any new therapeutic procedure in medicine.

Can one ever hope to determine if or when the clinical application of xenotransplantation is justified? The assessment of any experimental therapy, as Fox and Swazey (6) have suggested, should encourage the investigator to address three critical questions: 1) in the laboratory, what defines "success" sufficient to warrant advancement to the clinical arena? 2) under what clinical conditions should this advancement proceed? and 3) in the clinical arena, what defines "success" sufficient to warrant further evaluation (6)? Providing answers to this threefold inquiry requires a reliance upon defined "success," itself an appraisal of judgment that can only confidently be made in retrospect.

Because human heart transplantation is now considered by most justifiable for the treatment of end-stage heart disease, I would first like to review the history of cardiac allotransplantation in light of its ability to address the above threefold inquiry. I will also discuss the history of cardiac xenotransplantation with reference to scientific advances made in the field throughout the past quarter century. Finally, in light of these analyses, I hope to illustrate the role of baboon heart xenotransplantation as an alternative to allotransplantation for permanent cardiac replacement in the treatment of end-stage heart disease.

After the first human cardiac allograft procedure performed by Barnard in 1967 (7) the field of cardiac transplantation witnessed a surge in both enthusiasm and attempted trials, which was followed by a marked drop in procedures throughout the 1970s because of poor survival rates. During the initial peak, 21 human heart allotransplants were performed in the 6-month interval between December 1967 and June 1968 (with a cumulative 1-year survival of 22%), and 105 cardiac allotransplantations were performed in 1968 alone (8-10). However, these early clinical trials were marred by numerous failures, as 65% of persons undergoing the procedure before June 1970 died within 3 months of transplantation (6).

Few centers continued animal research and human procedures during the so-called black years of cardiac transplantation. The initial explosion in clinical trials accordingly elicited numerous responses suggesting that too much was being attempted too soon.

Some would propose that this was the price of eventual "success," and that further experimental studies at the time could not have avoided early
losses. And yet, there has been, and may always be, a tacit recognition by medical innovators that the ultimate experiment must be performed in humans, for no animal model can truly reflect the human condition. Proponents of allotransplantation at the time of the first heart transplantation cited the more than 60-year history of experimental cardiac transplantation, beginning with Carrel's original work in 1905. Although most of this work began in the 1930s, subsequent investigations regarding the experimental transplantation of mammalian hearts showed that cardiac transplantation was technically feasible and suggested the possibility of clinically relevant survival rates. During the decade before Barnard's first clinical application, cardiac allograft survival had been shown to exceed 250 days (mean 103 days) in adult dogs treated with an immunosuppressive regimen that included azathioprine and methylprednisone used intermittently. The mean survival in untreated dogs used as controls was 7 days (11).

Since that time, with further expansion of knowledge in virtually all areas of clinical cardiac transplantation, 1-year survival has increased from 67% in 1976, to approximately 85% reported currently at most hospital centers (3). Human recipients have survived for as long as 20 years after transplantation, and the 10-year posttransplant survival rate is now approximately 45% (12). While these figures depict a clear improvement in raw survival, cardiac transplantation is still not a cure for end-stage heart disease. Recipients must take immunosuppressive medication for life and be monitored for infection, rejection, and graft arteriopathy. However, these results are impressive considering that the recipient population today is considerably sicker than earlier allograft candidates. In light of these findings, few would deny cardiac allograft transplantation its present claim to "success." To further understand the evolution of this achievement, however, we may now look back upon the early years of cardiac allotransplantation and try to address the proposed threefold inquiry.

First, for Barnard and co-workers what can we presume as "success" warranting advancement to the clinical arena? They performed the first human adult cardiac allotransplantation when the maximum survival in immunosuppressed adult dogs had been 250 days (average survival 103 days) (11) and suggested that "against the background of this research . . . the time arrived when a cardiac transplant could be contemplated with hope of success" (7). Indeed, in their report of this case, they further described the scientific basis of their clinical advancement by explaining that "this achievement did not come as a surprise to the medical world. Steady progress toward this goal had been made by immunologists, biochemists, surgeons, and specialists in other branches of medical science all over the world during the past decades to ensure that this, the ultimate in cardiac surgery, would be a success" (7). Although we may, in retrospect, consider them justified in their declaration, in fact, at that time the endeavor was highly controversial and came as a surprise to much of the medical world.

Second, under what conditions did they proceed with this clinical trial? Given the "hope of success," Barnard and colleagues selected a patient "considered to have heart disease of such severity that no method of therapy short of cardiac transplantation could succeed" (7). The patient, a 54-year-old man, had remained in intractable congestive heart failure (following multiple myocardial infarctions) despite all medical management (13).

Finally, in this clinical arena, what defined for Barnard and colleagues "success" warranting further investigation? A concurrent editorial in the South African Medical Journal may provide some insight into their thinking: "The claim 'successful' can be used even at this early stage because to date it is a feat which makes medical history, no matter how short the further survival of the patient might be (4). "Success," by such an analysis, was thus not targeted posttransplant survival time, but rather any posttransplant survival time (given the ground-breaking nature of the endeavor). Further editorials regarding the ethics of cardiac transplantation viewed the procedure as a legitimate experiment but not a treatment (15), while in 1968, the American College of Cardiology suggested (with regard to the "success" of allotransplantation) that results varied: "... the spectrum of success ranges from short-term restoration of circulation to complete physical recovery" (16).

Indeed, "success" did vary along a spectrum of results. Barnard and colleagues' first allotransplant recipient lived for 18 days and ultimately died of pneumonia. However, their second recipient, 1 month later, survived more than 19 months before dying of chronic rejection (17). Their third
patient also lived more than 20 months after allo-
transplantation and ultimately died of carcinoma
of the stomach without signs of acute or chronic
rejection (18). One can only speculate how differ-
et the world reception to allotransplantation
would have been had the latter two patients rep-
resented the first and second recipients of cardiac
allotransplants. Would these survival data be con-
sidered “success,” or would they still pale in com-
parison with the theoretical goal of obtaining a
graft that could function normally indefinitely?

Clinical cross-species transplantation dates to
the early twentieth century, with kidney
xenografts from rabbit, pig, goat, non-human pri-
mate and lamb donors (19). After these early fail-
ures, the scientific literature was largely devoid of
reports of clinical xenotransplantation for nearly
40 years. In 1963, Reemtsma and colleagues
described six human recipients of chimpanzee kid-
nets, the longest survivor of whom died of causes
unrelated to rejection 9 months after xenotrans-
plantation (20).

The first cardiac xenotransplantation, per-
formed by Hardy in 1964, also represented the
first attempt at cardiac transplantation in hu-
mans, predating Barnard’s report by nearly 4
years (1). Since 1964, when Hardy and colleagues
at the University of Mississippi performed the
world’s first heart xenotransplant using a chim-
panzee as a donor, there have been eight docu-
mented attempts at clinical heart xeno-
transplantation. Five of these donors were non-
human primates (2 baboons, 3 chimpanzees) and
three were domesticated farm animals (1 sheep, 2
pigs) (21-25). The longest survivor was a newborn
infant with hypoplastic left heart syndrome.
“Baby Fae” was the recipient of an ABO-blood
group mismatched baboon heart that functioned
for 20 days (26). However, by the time the first
human neonatal cardiac xenotransplantation was
performed by Bailey in 1984 (the so-called “Baby
Fae” case), there had been only limited experi-
mental experience with prolonged graft survival
in the newborn xenotransplant recipient. Studies
presented by Bailey and co-workers shortly before
the Baby Fae case described a mean survival time
of 72 days in newborn lamb-to-goat xenotrans-
plants, with one survivor living to 165 days (27).

This advancement of xenotransplantation into
the clinical forum was met with resistance in the
medical community because of a perception that
research with acceptable survival “success” had
not been achieved experimentally. As Losman in
an editorial regarding the Baby Fae experience
stated, “It appears that this baboon-to-infant
transplantation did not rest on such a [scientific]
基础 [as did Barnard’s earlier operation in 1967]
”(28).

During the past 3 years, investigators at the
University of Pittsburgh reported two cases in
which they transplanted a baboon liver into a
human recipient, obtaining a 70-day survival in
their first reported case, and a 26-day survival in
the second (29; J. J. Fung, pers. comm.) The inves-
tigators’ overwhelming effort to prevent rejection
led them to use a harsh immunosuppressive regi-
men that permitted multiple life-threatening
infections. Rejection was not the major clinical
obstacle they encountered; therefore, they recom-
mended a more directed and less arduous immu-
nosuppressive regimen for future patients.

More alarming have been the attempts to apply
xenotransplantation of distantly related species
to the clinical arena. In 1968, both Cooley and
Ross transplanted sheep and pig hearts, respec-
tively, into dying human recipients (30,31). Both
grafts failed upon reperfusion, presumably be-
cause of hyperacute rejection.

More recently, Czaplicki and co-workers in
1992 described a case in which they attempted the
xenotransplantation of a pig heart into a human
recipient with Marfan’s syndrome (32). By their
report, no evidence of hyperacute rejection was
present at the time of death nearly 24 hours after
xenotransplantation. Their protocol used an un-
usual immunosuppressive regimen in which both
donor and recipient received, in addition to con-
ventional immunosuppression, both thymic tissue
extracts and fetal calf sera. This regimen also
included the extracorporeal perfusion of two pig
hearts with the recipient’s blood in an attempt to
remove human anti-pig antibodies before the or-
thotopic transplantation of the functional pig
heart (33). As astonishing as this case may be in
its extension to the clinical arena of a technique
not yet shown to be effective in the experimental
laboratory, it is not unique. Also in 1992, Makowka
and colleagues transplanted a pig liver into a
26-year-old woman dying of acute liver failure
from autoimmune hepatitis (pers. comm.). De-
spite the fact that, at present, it appears unlikely
that sufficient “success” has been achieved in the
laboratory regarding xenotransplantation be-
tween distantly related species to warrant
advancement to the clinical arena, these investigators were able to obtain approval from their hospital’s ethics committee and institutional review board to proceed with the clinical trial. Most experts in the field of xenotransplantation share the opinion that pig-to-human organ transplantation remains at least 3 to 5 years from clinical trials.

Considerable advances in the field of cardiac xenotransplantation have subsequently emerged worldwide since Hardy’s first clinical attempt in 1964, with a better understanding of the xenorejection process and a more sophisticated insight into mechanisms for its control. Extended graft survival has been achieved in a number of different experimental models, including a greater than tenfold graft survival in non-human primates treated with conventional cyclosporine-based immunosuppression (34,35), a more than thirtyfold increase in survival over controls described by Celli and colleagues in a rodent model (36), and survival beyond 1 year reported by Kawauchi and colleagues in a non-human primate model (37). These findings support the potential for achieving clinically relevant graft survival in humans.

The question is whether we have reached a stage in laboratory experimentation to justify further attempts at advancing cardiac xenotransplantation to the clinical arena. If we view the current status of experimental accomplishments in xenotransplantation with the same scrutiny as that of allotransplantation at the time of Barnard’s endeavor, we are left with similar conclusions; first, comparable graft survival time has been achieved in animal models of xenotransplantation as was evident for allotransplantation before 1967. Second, with our current understanding of cardiac allotransplantation has also come a greater awareness of its limitations. Thus, the conditions for the advancement of xenotransplantation arguably could be fulfilled by a patient with end-stage heart disease who is a candidate for allotransplantation, but for whom a donor cannot be identified in time. Therefore, it is reasonable to suggest both that we have reached a formidable limitation for precisely predicting the applicability of experimental laboratory evidence and that answers may only be sought from experiment in humans. This concept was realized by the American Medical Association with regard to allotransplantation, in reference to which it released an official statement acknowledging this notion in 1969 (38).

Concerns most commonly voiced with respect to the clinical application of xenotransplantation, however, pertain to a larger ethical controversy regarding human experimentation. Reemtsma, in a related comment concerning the Baby Fae case, suggested the following: “There is a widespread misperception that medical treatments and surgical procedures are easily classified as either experimental or accepted. In fact, all treatments have an element of experimentation, and new surgical procedures are based on extrapolations from prior work. . . . When does a surgeon decide to apply a new operation to a patient? . . . the decision is based on balancing, on the one hand, the experimental evidence suggesting that the procedure may succeed, and, on the other, the clinical urgency. . . (39).

Under what conditions will the clinical advancement of xenotransplantation proceed? For those initial patients in whom clinical xenotransplantation will first be applied, clinical urgency, in the complete absence of other suitable alternatives, undoubtedly will represent the motivating factor to proceed. Who will comprise this initial cohort? As Caplan has pointed out: “There would appear to exist a pool of terminally ill persons, both children and adults for whom no therapeutic alternatives exist or are likely to exist in the near
future... It would [thus] appear ethically defensible to allow research involving xenografting in human subjects to proceed in those areas where no reasonable alternative to therapy exists (40). In this context, innumerable reservations have been voiced regarding the ethics of proposing alternative experimental therapies to such patients for whom therapy has either failed or is non-existent. However, with regard to clinical experimentation under these circumstances, one must also recall (as Shimkin has suggested): “To do nothing, or to prevent others from doing anything, is itself a type of experiment, for the prevention of experimentation is tantamount to the assumption of responsibility for an experiment different from the one proposed” (41).

What is the goal of the clinical application of xenotransplantation? The need for donor organs irrefutably outweighs the resources available, and mechanical devices and xenotransplantation have emerged as the two most promising alternatives to allograft cardiac replacement. Mechanical left ventricular assist devices (LVADs) have witnessed relative success as “bridges” in carefully selected patients with heart failure. (A “bridge” is a temporary method of life support designed to carry a patient indefinitely until a human heart can be found and transplanted. It is not a “destination” therapy.)

Criteria for LVADs exclude patients with biventricular failure, and (because of the relatively large size of the device) patients with a total body surface area less than 1.5 square meters (~120 lb). Thus, many women and virtually all children are not candidates for mechanical left ventricular assistance. As has been the case for Food and Drug Administration protocols using LVADs, proposed investigations involving biologic assist devices (xenografts), have sought to evaluate a short-term alternative to allotransplantation in patients for whom a donor heart is not immediately available, and death is imminent. Only candidates who meet criteria for heart transplantation, but do not meet criteria for LVAD insertion, would be considered for a heart xenobridge. Similar clinical scenarios have been proposed for other solid organ transplants. Since they were first introduced by Cooley in 1969, temporary mechanical circulatory support devices have become critically useful tools in the therapeutic armamentarium available to patients awaiting transplantation (42). Nevertheless, at present, the widespread application of mechanical circulatory support is limited both by patient selection criteria and by the temporary nature of the device. For excluded patients, as well as many adult male candidates. For excluded patients, cardiac xenotransplantation may be the only reasonable alternative to cardiac allograft replacement.

Investigations in clinical xenotransplantation have been accused of using “the guise of [being a] bridge-to-transplantation” to appear acceptable to Institutional Research/Ethical Boards (5). However, the use of xenografts (or mechanical devices) solely as bridges to allotransplantation will not increase the donor pool, and, therefore, successful permanent xenotransplantation must itself be seen as the target for future clinical investigations. The goal of these studies is thus not to engage, as Hastillo and Hess (5) would suggest, in the “premature use of unproven procedures in fellow humans,” but rather to impact positively on the current shortage of human donor organs (6). In 1996, the clinical picture is no less bleak and the conclusions no less valid. The question that remains is not how but rather when xenotransplantation should advance to the clinical arena. Most of the uncertainties surrounding its advancement will only be answered by its undertaking.

In the foreseeable future, clinical xenotransplantation may achieve its targeted goal of extended graft survival. As was the case during the early years of allotransplantation, clinical xenotransplantation must persevere under the consideration of and often in spite of scrutiny by its most demanding critics, for while “success has a hundred fathers, failure is an orphan” (43).

Robert E. Michler
Director of Heart Transplant Service
Division of Cardiothoracic Surgery,
Columbia-Presbyterian Medical Center, New York, NY, USA

References